In a report released on March 27, Evan Seigerman from BMO Capital maintained a Buy rating on AbbVie, with a price target of $258.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evan Seigerman has given his Buy rating due to a combination of factors tied to AbbVie’s strong immunology portfolio and execution through major patent headwinds. He views Skyrizi’s superior clinical outcomes versus new oral competitors, along with its favorable labeling and patient preference for less frequent injections, as key supports for sustained demand and meaningful revenue contribution.
In addition, Seigerman notes that AbbVie remains commercially competitive through disciplined contracting and is managing the U.S. Humira loss of exclusivity from a position of strength. He also highlights upside from the Rinvoq franchise and the strategic acquisitions of ImmunoGen and Cerevel, which expand AbbVie’s oncology and neuroscience pipelines and underpin a solid long‑term growth outlook, reinforcing his positive stance on the stock.
In another report released on March 27, TipRanks – Google also reiterated a Buy rating on the stock with a $232.00 price target.